Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SON 1010 (Primary)
  • Indications Endometrial cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms SB-101
  • Sponsors Sonnet BioTherapeutics Holdings, Inc

    • Most Recent Events

    • 21 Jan 2025 According to a Sonnet BioTherapeutics Holdings media release, the company expects to enroll up to 18 patients with unresectable, metastatic liposarcoma or leiomyosarcoma in the expansion cohort.The Company believes the results of this expansion cohort could position SON-1010 for a larger Phase 2 study that could establish the combination of SON-1010 and trabectedin as a new and potentially improved treatment for STS.
    • 21 Jan 2025 According to a Sonnet BioTherapeutics Holdings media release, the company announced expansion of this Phase 1 study to add a new cohort to evaluate the effect of SON-1010 in combination with trabectedin ,it will explore the the immune-oncology impact of SON-1010 at the maximum tolerated (MTD) dose of 1200 ng/kg in combination with trabectedin.Enrollment in this cohort is expected to be completed in H1 2025 and topline date is expected in H2 2025.
    • 17 Dec 2024 According to a Sonnet BioTherapeutics media release, topline efficacy data of this trial is expected in H1 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top